Dr. John Burd, The Man Who Has Outsmarted Glycated Proteins
It is common knowledge that chronically elevated blood glucose levels as measured by the HbA1c are responsible for the devastating complications that affect the health of people with diabetes. Not only does this problem affect those patients already diagnosed, but this problem has the potential to negatively affect the lives of the millions of people who are pre-diabetic, too. The problem is nothing short of a ticking time bomb.
How do elevated blood glucose levels trigger those changes to the vascular, neurologic, and immune systems that negatively affect our health? One theory is that glycated proteins are responsible for many disease complications that affect both people with diabetes and non-diabetics, too.
A literature review reveals that glycated proteins can cause dysfunctional HDL that promotes senescence, atherosclerosis and skin aging. Glycated proteins also play a pathogenic role on diabetes and age-related dysfunction of the eye, including, diabetic retinopathy, cataract formation, and age-related macular degeneration. They play an important role in the diabetic complications of neuropathy, nephropathy, impaired wound healing, as well as cardiomyopathy, rheumatoid arthritis, and osteoporosis. The glycation theory of aging unites some of the neuropathological and biochemical findings in Alzheimer’s Disease and Dementia. As the research demonstrates, glycated proteins are a serious metabolic problem.
Battling the effects of chronically elevated blood glucose levels has traditionally been done by diabetes education, diet/nutritional counseling, medication, exercise and lifestyle modification. But there is now a new and innovative method to deal with this problem, developed by the man who has outsmarted glycated proteins.
Imagine taking a pill twice a day that would prevent the devastating complications of diabetes to the eyes, the kidneys and extremities caused by chronically elevated blood glucose and glycated proteins. Imagine still further that this pill would be available at the drug store, over the counter, without the need for a prescription and at a reasonable price. This is the dream that has become a reality of a San Diego biochemist, named Dr. John Burd who is no stranger to the world of diabetes. While Dr. Burd is not diabetic himself, he is surrounded by several close family members who do have diabetes. So, he has first-hand exposure to loved ones who are affected with the condition. Dr. Burd has a rich background in the area of biomedical development, having authored and co-authored numerous scientific articles and is the owner of 18 US patents. He was the Founder and CEO of Oculir, developing a non-invasive glucose testing technology and was Founder, President and CEO and of Dexcom, a leader in continuous glucose sensing technologies.
When I spoke with Dr, Burd he shared with me that in his research he has found that, “glucose is a toxic chemical. The kidneys are bathed in glycated proteins and this is where the damage begins.” With his experience and insights into the world of diabetes combined with his expertise in biochemistry, he has created an alternative method to control HbA1c levels AND prevent glycated proteins from damaging the health of people with diabetes. From a biochemical perspective Dr. Burd realized that “when glucose reacts with the amino acid Lysine, it can no longer react with proteins so that toxicity is lessened. Instead, a glycated amino acid is formed which the body removes in the urine.”
Dr. Burd has created a supplement called Lysulin, a patented formulation that contains Vitamin C, Zinc, and L-Lysine. He shared with me that, “20 years of research has shown that Lysine lowers glucose and glycated proteins. Zinc lowers glucose and glycated proteins and improves the lipid profile. Vitamin C lowers glucose and HbA1c.” And the proof? Dr. Burd shared the exciting results on HbA1c levels seen with volunteers who started taking Lysulin when it was recently introduced in January, 2018. The following figure illustrates the dramatic results seen after just one month taking Lysulin:
- 10.5 to 9.6 = 0.9
- 8.3 to 7.2 = 1.1
- 7.4 to 6.1 = 1.3
- 7.0 to 6.1 = 0.9
- 6.8 to 6.0 = 0.8
- 6.2 to 5.6 = 0.6
- 5.7 to 4.9 = 0.8
The average drop for 7 highlighted participants was 0.91 % HbA1c in one month.
While this new biochemical approach has multiple advantages over more traditional approaches to dealing with elevated HbA1c and glycated proteins, it would appear that the more dramatic benefit would be in managing this problem in locations who lack a sufficient number of physicians/providers and traditional medications to treat patients with diabetes. Lysulin is currently available on the Lysulin website at www.lysulin.com.